Reports

Ideas That Generate Results

List of Figures:

Figure 4-1: Global - Production Capacity and Production of Influenza Vaccine (Million Doses), 2009 & 2011
Figure 4-2: Global - Influenza Vaccine Sales (Million Doses), 2014 & 2020
Figure 4-3: Global - Influenza Vaccine Market (Billion US$), 2014-2020
Figure 4-4: Global - Influenza Vaccine Market by Players (%), 2014
Figure 4-5: Global - Fluzone/Vaxigrip Sales (Million US$), 2010-2014
Figure 4-6: Global - FluMist Sales (Million US$), 2010-2014
Figure 4-7: Global - Fluarix and FluLaval Sales (Million US$), 2010-2014
Figure 4-8: Global - Anflu Sales (Million Doses), 2010-2013
Figure 4-9: Global - Anflu Sales (Million Doses), 2010-2013
Figure 4-10: Global - Afluria/Fluvax Sales (Million US$), 2012-2014
Figure 4-11: Global - Flucevax and Fluvirin Sales (Million US$), 2012-2014
Figure 5-1: Global - Influenza Vaccine Market by Region (%), 2014
Figure 5-2: US - Influenza Vaccine Sales (Million Doses), 2009-10 to 2014-15
Figure 5-3: US - Influenza Vaccine Market by Players (%), 2014
Figure 5-4: US - Influenza Vaccine Market (Billion US$), 2014-2020
Figure 5-5: Europe - Influenza Vaccine Market by Players (%), 2014
Figure 5-6: Europe - Influenza Vaccine Market (Million US$), 2014-2020
Figure 5-7: Europe - Seasonal Influenza Vaccination Coverage in Older Age Group by Country (%), 2011-12 & 2012-13
Figure 5-8: Emerging Markets - Influenza Vaccine Market by Players (%), 2014
Figure 5-9: Emerging Markets - Influenza Vaccine Market (Million US$), 2014-2020
Figure 5-10: Rest of the World - Influenza Vaccine Market (Million US$), 2014-2020
Figure 8-1: Sanofi - Breakup of Total Revenues by Business Segment (%), 2014
Figure 8-2: Sanofi Pasteur - Breakup of Vaccine Segment by Type (%), 2014
Figure 8-3: Sanofi Pasteur - Breakup of Total Influenza Vaccine Revenues by Geography (%), 2014
Figure 8-4: GlaxoSmithKline Plc - Breakup of Total Revenues by Business Segment (%), 2014
Figure 8-5: GlaxoSmithKline Plc - Breakup of Vaccine Segment by Type (%), 2014
Figure 8-6: GlaxoSmithKline Plc - Breakup of Total Influenza Vaccine Revenue by Geography (%), 2014
Figure 8-7: CSL Ltd - Breakup of Total Revenues by Business Segment (%), 2014
Figure 8-8: CSL Ltd - Breakup of bioCSL Revenues by Product Type (%), 2014
Figure 8-9: AstraZeneca Plc - Breakup of Total Revenues by Business Segment (%), 2014
Figure 8-10: AstraZeneca Plc - Breakup of Infection Segment by Type (%), 2014
Figure 8-11: AstraZeneca Plc - Breakup of Total Influenza Vaccine Revenues by Geography (%), 2014
Figure 8-12: Sinovac Biotech - Breakup of Vaccine by Type (%), 2013

List of Tables:

Table 5-1: US - Major Influenza Vaccines & Manufacturers (2014-15)
Table 5-2: Percentage of People in the US Who Received Influenza Vaccine (2013-14)
Table 5-3: Number of Pediatric Deaths in US Flu Season (2005-06 to 2014-15)
Table 5-4: US - Seasonal Influenza Vaccination Coverage by Group (%), 2011-12 to 2013-14
Table 5-5: Europe - Major Influenza Vaccines & Manufacturers (2014-15)
Table 5-6: China - Vaccine Classification
Table 5-7: Australia - Major Influenza Vaccines & Manufacturer (2014-15)
Table 6-1: Influenza Vaccine - Pipeline Analysis, 2014
Table 7-1: Major Influenza Vaccines Cost/Dose (US$) for 2015-16 Season
Table 8-1: Sanofi - Key Financials (Million US$), 2012-2014
Table 8-2: Influenza Vaccines Offered by Sanofi Pasteur (2014)
Table 8-3: GlaxoSmithKline Plc - Key Financials (Million US$), 2012-2014
Table 8-4: Influenza Vaccines Offered by GlaxoSmithKline Plc (2014)
Table 8-5: CSL Ltd. - Key Financials (Million US$), 2012-2014
Table 8-6: CSL Influenza Vaccine Portfolio before Merger
Table 8-7: CSL Influenza Vaccine Portfolio after Merger
Table 8-8: AstraZeneca Plc - Key Financials (Million US$), 2012-2014
Table 8-9: Influenza Vaccines Offered by AstraZeneca Plc (2014)
Table 8-10: Sinovac Biotech - Key Financials (Million US$), 2011-2013
Table 8-11: Influenza Vaccines Offered by Sinovac Biotech (2014)